Washington University School of Medicine in St. Louis | Strategic Alliance Partners
Latest from Washington University School of Medicine in St. Louis
Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL
Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.
Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors
June 16th 2023Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.
Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma
June 15th 2023Treatment with duvelisib led to a high response rate in patients with peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma.
Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma
June 9th 2023Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.
ABBV-011 Showcases Early Tolerability, Antitumor Activity in Small Cell Lung Cancer
The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.
Jumping Genes in Cancer Cells Open Door to New Immunotherapies
May 5th 2023Research from Washington University School of Medicine in St. Louis suggests that transposable elements in various cancers potentially may be used to direct novel immunotherapies to tumors that don’t typically respond to immune-based treatments.
Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments
May 2nd 2023Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.
Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
April 20th 2023Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Practice-Changing Trials Expand Armamentarium and Improve Guidance in Advanced Breast Cancers
April 13th 2023Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice.
Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models
April 12th 2023Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.
Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models
April 12th 2023Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.
